CAMBRIDGE, Mass.–(BUSINESS WIRE)– Genocea Biosciences, Inc. RUSSELL, BVSc, PhD, FRCPath, MRCVS Department of Pathology and Infectious Diseases, The Royal Veterinary College, Royal College Street, Herpes simplex virus-2 (HSV-2) is the most common cause of genital herpes. . Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. Statements herein relating to future business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements.
T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, November 3, 2016 at 9:00 a.m. About Genital Herpes Genital Herpes affects more than 400 million people worldwide and causes recurrent, painful genital lesions. Genocea also announced this morning a new collaboration with US Oncology Research, one of the USA’s largest research programs specializing in oncology clinical trials, to screen the T cell responses of cancer patients with solid tumors who will be treated with checkpoint inhibitors against the complete repertoire of patient-specific putative cancer neoantigens. It is a first in class molecule derived from a novel chemical class and is designed to inhibit the HCMV viral terminase. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Department of Health and Human Services.
(MSD) in 2012, just met the primary endpoint in a pivotal phase 3 study and probably could be the first drug derived from AiCuris’ development activities that enters the market in the near future. Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. ATLAS screening has already identified novel T cell antigens, including those which appear to be associated with natural immunity against EBV infection and antigen selection and prioritization is ongoing. The weekly data also show an oversold stock, with a negative MACD. (LCI – Free Report) . The Motley Fool has a disclosure policy. Genocea plans to use these insights to help prospectively define, in a commercial or clinical setting, patients who could benefit from these therapies.
Well, before we can consider any sort of approval potential, Genocea must first find a commercial partner to help get GEN-003 into – and through – phase 3 trials. There is no approved vaccine for HSV-2. Astellas expects the top-line trial data to be available in the third quarter of 2016. Mr. HSV-2 infection also significantly increases the risk of acquiring HIV-1. Subjects will be followed for 12 months after the last dose. Last September, the company announced that the study achieved primary endpoint with GEN-003 demonstrating a statistically significant reduction of 40% in the rate of viral shedding in the 60 µg per antigen / 50 µg of adjuvant dose group in comparison to both baseline and placebo.
GEN-004 reduced the colonization rate, measured by microbiological culture, by between 22 and 25 percent versus placebo across those measurement time points. Mammen will be available on Vical’s website after the presentation. Try any of our Foolish newsletter services free for 30 days. The company is expected to announce data from the study later in the first quarter of 2016. Coming back to the press release, data showed that GEN-003 demonstrated statistically significant improvements in comparison with placebo across multiple clinical endpoints at six months after dosing. Now What: Genocea has been quite active at tapping the markets to increase its cash position recently, as this is the second time the company has performed a secondary offering this year. The company highlighted its lead program, GEN-003, a T cell-directed immunotherapy for the treatment of genital herpes infections for which six-month Phase 2b placebo-controlled clinical efficacy is expected in January 2017.
Besides this role, Prof. Of course, Feuerstein has – as yet – remained quiet, and indeed, there is some discussion among shareholders suggesting he is denying the initial output. GEN-003 is a candidate therapeutic vaccine containing recombinant HSV antigens gD and ICP4 along with Matrix M-2 (MM) adjuvant. The biotech firm continues to commercialize key breakthroughs in vaccine discovery and development since its founding in 2006, paying specific attention to the development of vaccines that harness the body’s immune response using T-cells to target specific disease-causing organisms such as Herpes Simplex Virus Type 2 (HSV-2).